Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer

Virginia Kaklamani • 12 Dec 2024
SABCS 2024
Breast Cancer Elacestrant
ELCIN EMERALD

Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Based on the findings of the EMERALD trial (NCT03778931), which demonstrated significant progression-free survival benefits for elacestrant, the ELCIN trial further explores its efficacy and safety. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Virginia Kaklamani

Optimizing treatment approaches for ER+/HER2- breast cancer
1:19
Optimizing treatment approaches for ER+/HER2- breast cancer
Virginia Kaklamani • 12 Dec 2024
SABCS 2024 highlights: assessing the clinical impact of EMBER-3 and PATINA
1:02
SABCS 2024 highlights: assessing the clinical impact of EMBER-3 and PATINA
Virginia Kaklamani • 12 Dec 2024
Should germline genetic testing be universal for patients with breast cancer?
1:14
Should germline genetic testing be universal for patients with breast cancer?
Virginia Kaklamani • 12 Dec 2024
Highlights from SABCS 2023: the future of immunotherapy in higher-risk ER+ breast cancer
1:31
Highlights from SABCS 2023: the future of immunotherapy in higher-risk ER+ breast cancer
Virginia Kaklamani • 12 Dec 2023

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals